esomeprazole + pritelivir

The combination of esomeprazole and pritelivir is primarily investigated in clinical pharmacology studies to evaluate drug-drug interactions, specifically the impact of gastric acid suppression on the pharmacokinetics of pritelivir. **Pritelivir** (formerly AIC316) is a first-in-class, potent small molecule inhibitor of the viral helicase-primase enzyme complex, developed by **AiCuris** for the treatment of herpes simplex virus (HSV) infections, including acyclovir-resistant strains. **Esomeprazole** is a proton pump inhibitor (PPI) and the S-isomer of omeprazole, which reduces gastric acid secretion by inhibiting the H+/K+-ATPase pump in parietal cells. Phase 1 trials (e.g., NCT02846311) have utilized this combination to determine if the increased gastric pH induced by esomeprazole affects the absorption and systemic exposure of pritelivir, which is critical for optimizing dosing in patients who may be co-prescribed acid-reducing therapies.

Other names

esomeprazole and pritelivirpritelivir and esomeprazole